Liquidia (LQDA) Insider Damian Degoa Buys 5,882 Shares

Damian Degoa recently purchased 5,882 shares of Liquidia Corporation (NasdaqCM: LQDA) on June 16, 2026. This insider buy comes as Liquidia's stock trades at $69.02.

Insider Buying and Selling at Liquidia Corporation

On June 16, 2026, several insiders, including Damian Degoa, each acquired 5,882 shares of Liquidia Corporation. These transactions were not part of any pre-planned trading program. Other insiders participating in similar purchases on the same day include Stephen Bloch, Katherine Rielly-Gauvin, Paul Manning, Joanna Horobin, and Arthur Kirsch.

Other Institutional Activity in Liquidia Corporation

In recent institutional activity, Findell Capital Management LLC increased its stake in Liquidia by 650,663 shares, ending with a total of 3,502,112 shares valued at approximately $132.2 million. BlackRock, Inc. also added 781 shares, bringing its total to 5,489,144 shares worth about $207.2 million. Meanwhile, Opaleye Management Inc. grew its position by 110,000 shares to 2,545,000 shares, valued at $88.8 million. Farallon Capital Management LLC and Caligan Partners LP maintained their positions without any changes.

Liquidia Corporation Stock Up 98.4%

Shares of Liquidia Corporation are currently trading at $69.02. The company has a market capitalization of approximately $6.1 billion and a forward P/E ratio of 12.32. Liquidia's stock has seen a 52-week low of $11.85 and a high of $73.22. The stock's 50-day moving average is $51.34, while its 200-day moving average is $36.69. The company maintains a current ratio of 2.22 and a quick ratio of 1.98, with a debt-to-equity ratio of 170.22.

Recent Earnings

Liquidia reported revenue of $288.1 million, reflecting a growth of 41.59%. The company achieved a net margin of 7.74% and a return on equity of 28.18%. Earnings per share stood at $0.17. The next earnings release is scheduled for August 12, 2026.

Analysts Set New Price Targets

On June 5, 2026, HC Wainwright & Co. maintained its 'buy' rating for Liquidia with a price target of $75. Earlier, in May, Wells Fargo and Needham also maintained 'buy' ratings with targets of $62 and $70, respectively. The consensus among analysts is a strong buy, with a mean target price of $66.13 based on eight analyst opinions.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company based in Morrisville, North Carolina. It focuses on developing and commercializing products for rare cardiopulmonary diseases. The company's lead product, YUTREPIA, is an inhaled dry powder for treating pulmonary arterial hypertension. Liquidia also develops Remodulin, a treprostinil injection, and L606, an investigational formulation in phase III clinical trials. Founded in 2004, the company employs 216 people and is led by CEO Dr. Roger A. Jeffs.

Bottom Line

Damian Degoa's recent purchase of Liquidia shares highlights ongoing insider interest in the company. Liquidia's stock performance and analyst ratings suggest optimism, with a strong buy consensus among analysts. Investors will be watching upcoming earnings for further insights into the company's growth trajectory.